Clinical Outcomes Associated with Use of Subcutaneous Sliding Scale Insulin Compared to Other Insulin Regimens in Hospitalized Patients

Background: Hyperglycemia in hospitalized patients is managed through one of the following approaches: sliding scale insulin (SSI) alone; SSI plus long-acting insulin and basal-bolus insulin (BBI). The optimal insulin treatment regimen is still debated. Objectives: To evaluate the clinical outcomes associated with the use of SSI compared to other regimens. Setting: The general medical wards in King Abdulaziz Medical City, Riyadh, Saudi Arabia. Methods: Medical charts for adult patients admitted between October 2014-December 2015 with type 2 diabetes or uncontrolled hyperglycemia with insulin treatment were reviewed. Data from capillary blood glucose were measured daily for the first 5 days of hospitalization and recorded. Demographics and blood glucose levels were compared by group using one-way ANOVA or Chi-square test. The number of hyperglycemic/hypoglycemic episodes was analyzed using the Kruskal-Wallis test. Results: A total of 240 patients were included. The three insulin regimen groups were not statistically different in terms of the number of days with episodes of hyperor hypoglycemia (p > 0.05). However, a significantly bigger change from baseline (improvement) in random blood glucose (RBG) levels was observed in BBI and SSI plus glargine patients compared to SSI (p = 0.014). Conclusion: Our study showed no significant difference in the number of days with episodes of hyperor hypoglycemia for SSI vs. other insulin regimens. However, SSI patients had less improvement in their RBG levels compared to other insulin regimen How to cite this paper: Alfehaid, L.S., Alotaibi, A.S., Alanazi, A.S., Bustami, R.T. and El Melik, R. (2018) Clinical Outcomes Associated with Use of Subcutaneous Sliding Scale Insulin Compared to Other Insulin Regimens in Hospitalized Patients. International Journal of Clinical Medicine, 9, 260-269. https://doi.org/10.4236/ijcm.2018.94023 Received: March 16, 2018 Accepted: April 24, 2018 Published: April 27, 2018 Copyright © 2018 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0). http://creativecommons.org/licenses/by/4.0/


Introduction
Diabetes is considered one of the most common leading causes of death. The epidemiologic data indicate that 347 million people worldwide have diabetes [1], whereas in Saudi Arabia the prevalence of diabetes is 34.1% in males and 27.6% in females [2]. The most common form of diabetes is type 2 diabetes which represents about 90% -95% of diabetic patients and is associated with obesity, older age, physical inactivity and family history [3]. Type 2 diabetes can be defined as an impaired utilization or insufficient amount of insulin that is produced by the pancreas which progresses slowly over time. Uncontrolled diabetes in majority of hospitalized patients is associated with increased risk of morbidity and mortality, increased the length of hospital stay and re-hospitalization rate [4] [5] [6].
The American Diabetes Association and the American College of Endocrinology recommend that glucose levels of all patients admitted to non-critical-care units should be maintained below 180 mg/dL (10.0 mmol/L) [7] [8]. Currently, hyperglycemia in hospitalized patients is managed through one of the following approaches of three approaches: sliding scale insulin (SSI) alone; every 6 hours as needed, SSI plus long-acting insulin (glargine) and basal-bolus insulin (BBI); (glargine once daily plus lispro insulin before meals). SSI has been used as the standard practice for diabetic patients since 1934 [9]. SSI is defined as the progressive increase in rapid or short-acting insulin in addition to scheduled insulin doses in order to maintain blood glucose levels within the desired targets. However, the use of SSI is not optimal due to the poor glycemic control it provides.
Recent randomized clinical trials showed that the use of BBI proved to be more effective than SSI in terms of achieving the desired blood glucose levels in hospitalized patients with type 2 diabetes [10] [11]. BBI treatment has been also shown to reduce morbidity in patients undergoing surgery [12]. BBI is based on giving long-acting insulin to maintain consistent blood glucose levels during fasting periods while taking into consideration the use of short-acting insulin injections to prevent potential increases in blood glucose levels caused by meals [13]. SSI plus long-acting insulin (glargine insulin) is based on a tight control of blood glucose levels throughout the day. SSI is not considered an ideal approach for controlling hyperglycemia due to a number of disadvantages it has; SSI does not take into consideration the requirements of basal insulin to prevent inter-meal and nocturnal hyperglycemia, or patient history concerning the use of International Journal of Clinical Medicine insulin (resistance-sensitivity), diet or other characteristics. Furthermore, while SSI is used for treating hyperglycemia, it does not prevent hyperglycemia from occurring in the future, so it is not a proactive approach but rather reactive [14].
The assessment of glycemic control while using SSI is not regularly done. That is, diabetic patients do not get an immediate intervention from the health care provider unless blood glucose levels reach more than 396 mg/dL (22.2 mmol/L) or less than 59.4 mg/dL (3.3 mmol/L) [15].

Aim of the Study
Evaluate the treatment approach for acute hyperglycemia in hospitalized patients managed with SSI alone and compare its clinical outcomes with those using other insulin management approaches. Another objective of this study is to increase the awareness of medical teams in terms of the choice of the treatment approach for type 2 diabetes.

Ethics Approval
This retrospective observational study was approved by King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia.

Statistical Analysis
Descriptive statistical analyses were initially performed for the study sample.
Continuous variables were summarized using average and standard deviation, median and range. Proportions were used for categorical variables. To examine comparability of insulin regimen groups, baseline demographic and clinical factors were evaluated and compared in the three regimen groups. In-hospital blood glucose levels, as well as the number of days with hyperglycemia or hypoglycemia based on FBG and RBG, were evaluated and compared.
Categorical data were analyzed using Chi-square test. The distribution of all continuous data was examined. For continuous variables whose distributions approximate normality, one-way ANOVA was used for comparisons. When normality assumptions were not satisfied, the non-parametric Kruskal-Wallis test was utilized. Statistical significance was considered at p < 0.05. All statistical analyses were performed using SPSS 21.0 [Release 21.0.0.0].
To account for baseline blood glucose levels, multivariate linear regression analyses were employed to predict in-hospital FBG and RBG by insulin regimen group. Adjustments were made for age, gender, and blood glucose level at baseline.

Results
A total of 240 patients were included; 80 in SSI regimen group, 99 in SSI plus glargine regimen group and 61 in BBI regimen group. The average age was 69.1 years (SD = 12.2), with 52% males. Overall, average baseline hemoglobin A1C was 9.3% (SD = 2.4); baseline RBG was 268.2 mg/dL (14.9 mmol/L) (SD = 6.6) and baseline FBG was 175.5 mg/dL (9.75 mmol/L) (SD = 4.3). Table 1 shows descriptive statistics and comparison of demographic and baseline factors in the three insulin regimen groups. The three groups were significantly different in terms of baseline RBG (average ± SD: 232.2 (12.9 ± 6.7) for SSI, 279 (15.5 ± 6.3) for SSI plus glargine and 298.8 (16.6 ± 6.4) for BBI; (p = 0.001). Baseline FBG was also significantly different in the three groups 153 (8.5 ± 3.4) for SSI, 189 (10.5 ± 4.3) for SSI plus glargine and 172.8 (9.6 ± 4.9) for BBI; p = 0.028). The SSI group patients were significantly younger than other insulin group regimens (p = 0.014), while hemoglobin A1C was not statistically different in the three groups (p > 0.05). While a significantly bigger change from baseline (improvement) in RBG levels was observed in the BBI and SSI plus glargine patients compared to SSI (p = 0.014) ( Table 1), there were no significant differences between the three groups in terms of number of hyperglycemic days based on FBG (median days was 3.0 for all groups; p = 0.41) or RBG (median days was 3.0 for both SSI and BBI and 4 days for SSI plus glargine; p = 0.20) (Table 2). Also, there were no significant differences between the three groups in terms of the number of hypoglycemic days based on FBG (median days was 0 for all groups, with a range of 2 -4 days; p = 0.88) ( Table 3)      However, no significant differences were found between groups in terms of in-hospital FBG (not shown).

Discussion
This study was conducted to compare three insulin regimen approaches in the hospital; SSI, SSI plus glargine, and BBI. This study demonstrates that there was no significant difference in the number of days with episodes of hyper-or hypoglycemia associated with the use of SSI compared to other two insulin regimen approaches used for prevention or treatment of acute hyperglycemia in general medical hospitalized patients. While we observed a significant difference between the groups in terms of in-hospital RBG levels with higher levels detected among patients treated with SSI plus glargine or BBI, our study showed no significant differences between the three insulin treatment groups in terms of hyperglycemic days. These results differ from previous observational studies in diabetic hospitalized patients, where blood glucose values were significantly higher in patients treated with SSI compared to those treated with either long-acting insulin regimens or combination of SSI and long-acting insulin [16] [17]. Also, our findings contradict a recently published randomized control trial which demonstrated that SSI insulin was associated with hypoglycemia with blood glucose lower than 72 mg/dL (4 mmol/L) more than BBI, while no association was found with severe hypoglycemia indicated by blood glucose levels lower than 45 mg/dL (2.5 mmol/L) [18]. In contrast, our findings were similar to those obtained in a study comparing SSI with BBI among non-critically ill patients where no significant difference was found between the two insulin regimens in terms of the incidence of moderate or severe hypoglycemia [19]. However, it is important to recognize that baseline blood glucose measures for SSI patients were significantly lower compared to those treated with BBI or SSI plus glargine. This may be related to the preference of ordering the SSI regimen for those patients when hypoglycemia is a major concern. Also, results from a prospective randomized control trial comparing the use of BBI with SSI alone International Journal of Clinical Medicine showed that the BBI group had greater improvement in blood glucose control compared to SSI [20]. Nevertheless, the data revealed no difference in the number of days with hypoglycemia in the three groups. This result contrasts other previous studies, where tight glycemic control patients experienced the higher rate of hypoglycemia compared to those on the SSI regimen [20] [21]. Most of these studies focused on critically ill patients, and in our study, several patients had received nothing by mouth which could be a possible explanation for this result as the SSI practice involve administration of short-acting insulin regardless of whether the patient is receiving food or not. A similar retrospective study conducted on non-critically ill patients found that tight glycemic control patients are more likely to have their blood glucose levels at goal with the lower risk of hypoglycemia compared with the patient treated with SSI alone [16]. Also, SSI patients are more likely to have their blood glucose levels checked using blood glucose meters compared to other groups. This is in addition to numerous insulin injections, thus increasing discomfort for those patients and potentially increasing the risk of advanced micro-or macrovascular complications that may negatively impact the quality of life particularly for elderly and long-term hospitalized patients.
This study has number of limitations. First, the design is retrospective where the choice of treatment was purely at the discretion of the treating clinician, which may have generated bias. Secondly, our study suffers from a relatively small sample size limiting our ability to detect other possible significant predictors of blood glucose control. Therefore, our results may not be generalizable to all diabetic hospitalized patients. Furthermore, this study did not examine the International Journal of Clinical Medicine impact of glycemic control on patient outcomes. Patients were followed for only 5 days, which may not be enough time to show the complete effect of glycemic control using insulin.
Despite these limitations, our study has several strengths. First, it was aimed at evaluating and comparing the SSI approach with other insulin regimens that are commonly used as interventions in prevention or treatment of acute hyperglycemia in hospitalized patients. Only a few studies have focused on comparing these 3 approaches in non-critically ill patients. Additionally, we have used the average as a summary of all available blood glucose measures instead of arbitrarily selecting measures to assess the difference in blood glucose control between groups thus minimizing the potential bias from neglecting important values that may impact outcomes. Finally, the study population was well-defined with rigorous inclusion criteria. In fact, majority of data were prospectively collected during the study duration and for a long observation period which adds to the quality of recorded data.

Conclusion
While we found a significant difference between insulin regimen groups in terms of in-hospital RBG levels, no statistically significant difference was observed in the number of days with episodes of hyper-or hypoglycemia associated with the use of SSI versus other insulin regimen groups. Further studies using a larger sample size are needed to confirm these findings.